Clinical trial · no report yet · Phase 3
NCT03775265
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- NCT03775265 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 13 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Atezolizumab; Biopsy of Bladder; Cisplatin; Computed Tomography; Cystoscopy; Fluorouracil; Gemcitabine; Magnetic Resonance Imaging; Mitomycin; Quality-of-Life Assessment; Radiation Therapy; Survey Administration; Transurethral Resection of Bladder Tumor
- Arms
- Arm I (RT, chemotherapy) · Active comparator
- Arm II (RT, chemotherapy, atezolizumab) · Experimental
- Enrollment
- 475 (estimated)
- Primary outcomes
- Bladder intact event-free survival (BI-EFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 3, 2019
- Primary completion
- Jun 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03775265 · updated Aug 28, 2026